Un tratamiento viral elaborado con el plasma de caballos inmunizados es la esperanza de Costa Rica para enfrentar la creciente propagación de la covid-19 en el
Un tratamiento viral elaborado con el plasma de caballos inmunizados es la esperanza de Costa Rica para enfrentar la creciente propagación de la covid-19 en el país, y evitar la amenaza de saturación de los hospitales públicos. (Fuente: AFP)
:quality(75)/cdn.jwplayer.com/v2/media/m6kCCHqq/poster.jpg)
:quality(75)/dvgnzpfv30f28.cloudfront.net/10-03-2020/t_c0e96bd6154c43dc859f52d3307032a6_name_file_640x360_600_v3_.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/E5G5HWYWUNHFDHML3RA3HBN6BI.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/NJYRXMWTJNBH7AG5CKMEOLNJ7E.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FACEUXZLE5DNHFQEAYVP66PHSI.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/VYBtNakX/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/o1KPg1hs/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/TvvzxktF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/rtpKhHdf/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/NJYRXMWTJNBH7AG5CKMEOLNJ7E.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FACEUXZLE5DNHFQEAYVP66PHSI.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ZJRMYQTLGVFTTCQZDWD6JUNJ34.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/HQ6UNSPCJFBRZG6O34HWHMLUTM.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/m6kCCHqq/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/QxMVfmg2/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X4VBIZZSUJGXBGIJOXH57ZBV3E.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/UCjyX8ro/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/E5G5HWYWUNHFDHML3RA3HBN6BI.png)
:quality(75)/cdn.jwplayer.com/v2/media/DnqOfjf2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Qu9HnWcU/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/IJVmPJJM/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/koNs9MA2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/6bLTGi5d/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/KgeU8b6Q/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/a6mwPQ4X/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X3PAJUVAAFHRXHUYV5TON7UAAY.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/yksVgSj8/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/wXUo9jVU/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/nu9nKgwG/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/c0S03whF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/azLadx4o/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FQ5XSTUGQ5DI3DYDC3MUSLQL6A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9a1H4G0a/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/yOEdb2ys/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/JDVYxTbd/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/LIy1dI2W/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Xv8iJGpA/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/JW2JBE7IBZEY5NR2VH4KVTPGZ4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/42WZKDIDGVA6VKQDF75376W2CA.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ENCJ6JEIFZHT5E6UXK3KZ5RCUU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UZ27WLDNBFBCPCMLG42DQCNJYA.png)